Therapy
Anthracyclines, including daunorubicin (DNR), idarubicin (IDA),
mitoxantrone (Mito), pirarubicin (THP) or homoharringtonine (HHT),
combined with cytarabine (Ara-C), FLAG (fludarabine, cytarabine,
granulocyte colony stimulating factor) combined with idarubicin and DAE
(DA combined with etoposide) were main induction therapies.
Consolidation regimens included standard dose Ara-C (SDAC)-based and
median dose Ara-C (MDAC)-based regimens, as previously reported [4,
7]. ICE (idarubicin, cytarabine, etoposide), CAG (aclarubicin,
cytarabine, granulocyte-colony stimulating factor), FLAG and CLARA
(cladribine and cytarabine) were used as salvage therapies.
Allo-transplant was mainly performed in patients carrying c-KIT
mutations and in those who had not achieved complete response (CR) after
two cycles of induction therapies.